跳至主要内容
临床试验/NL-OMON23691
NL-OMON23691尚未招募不适用

Early Detection of Immunotherapy-mediated Toxicity

Erasmus MC0 个研究点目标入组 50 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
Erasmus MC
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 1. Population with immunotherapy-related organ specific toxicity
  • ? Planned treatment with (intravenous) checkpoint inhibitors for any type of cancer
  • according to standard of care.
  • ? Age =18 years
  • ? Able to understand the written information and able to give informed consent
  • 2. Population with immune-mediated organ specific disease
  • ? Patients with immune-mediated organ specific disease including, but not limited to,
  • immune-mediated colitis such as ulcerative colitis, Crohn’s disease or auto-immune
  • ? Age =18 years
  • ? Able to understand the written information and able to give informed consent

排除标准

  • 4.2 Exclusion criteria
  • ? Unable to draw blood for study purposes

研究者

发起方
Erasmus MC

相似试验